- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ALLARITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Allarity Acquisition Corp. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| Di | Allarity Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | Allarity Therapeutics, Inc.: Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research | 199 | GlobeNewswire (Europe) | - Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity's research capabilities to enable... ► Artikel lesen | |
| 14.09. | Allarity Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Allarity Acquisition Seeks Nasdaq Listing With Proposed $100 Mln IPO | 921 | AFX News | WASHINGTON (dpa-AFX) - Friday, Allarity Therapeutics, Inc. (ALLR) announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company, has filed for a proposed initial... ► Artikel lesen | |
| 11.09. | Allarity Therapeutics files for $100 million SPAC offering | 3 | Investing.com | ||
| 11.09. | Allarity Therapeutics, Inc.: Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement | 492 | GlobeNewswire (Europe) | TARPON SPRINGS, Fla., September 11, 2026 - Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a... ► Artikel lesen | |
| 10.09. | SPAC Allarity Acquisition files for a $100 million IPO, targeting life sciences and biotech | 4 | Renaissance Capital | ||
| 10.09. | Allarity Acquisition Corp. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 14.08. | Allarity Therapeutics reports Q2 results | 1 | Seeking Alpha | ||
| 14.08. | Allarity Therapeutics reports Q2 results, cash position | 2 | Investing.com | ||
| 14.08. | Allarity Therapeutics, Inc.: Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign | 703 | GlobeNewswire (Europe) | - Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP- companion diagnostic... ► Artikel lesen | |
| 14.08. | Allarity Therapeutics, Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 07.07. | Allarity Therapeutics erhält CLIA-Zertifizierung für Labor in Dänemark | 2 | Investing.com Deutsch | ||
| 01.07. | Allarity Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Allarity receives U.S. patent for stenoparib diagnostic test | 1 | Investing.com | ||
| 22.06. | Allarity Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.06. | Allarity Therapeutics, Inc.: Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 | 4 | GlobeNewswire (USA) | ||
| 02.06. | Allarity Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.05. | Allarity Therapeutics GAAP EPS of -$0.17 beats by $0.05 | 2 | Seeking Alpha |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| PFIZER | 24,735 | +0,18 % | Litfulo and tilrekimig data bolster Pfizer's immunology plans | ||
| MERCK KGAA | 136,90 | +1,82 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| GILEAD SCIENCES | 128,68 | +0,09 % | Assembly Biosciences: Herpes-Countdown mit Gilead | ||
| AURORA CANNABIS | 3,518 | +0,86 % | Aurora Cannabis: Beschwerde bringt den Deal ins Wanken | ||
| ABBVIE | 231,00 | -0,35 % | AbbVie To Present New Dermatology Data At 2026 EADV Congress | WASHINGTON (dpa-AFX) - AbbVie (ABBV) said it will present new clinical and real-world data across its dermatology portfolio at the 2026 European Academy of Dermatology and Venereology (EADV)... ► Artikel lesen | |
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma | ||
| CANOPY GROWTH | 0,780 | +0,72 % | Canopy Growth Corporation: Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany | Mr. Blöte's appointment strengthens Canopy Growth's commercial leadership as it drives growth across its European medical cannabis businessCanopy Growth Corporation ("Canopy Growth", "our", "we" or... ► Artikel lesen | |
| MERCK & CO | 128,18 | 0,00 % | AstraZeneca-Summit, Novo-Hengrui, Merck-Fierce Pharma Asia | ||
| ASTRAZENECA | 139,30 | 0,00 % | Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy | ||
| TILRAY BRANDS | 3,215 | +0,31 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 54,11 | -0,39 % | Dividendenbekanntmachungen (02.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACME UNITED CORPORATION US0048161048 0,16 USD 0,1423 EUR ALICO INC US0162301040 0,05 USD 0,0444 EUR ATN INTERNATIONAL INC US00215F1075 0... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 34,600 | -1,14 % | XFRA TEVA: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILTEVA PHARMACEUT.... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 448,45 | +0,04 % | $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today |
ALLARITY THERAPEUTICS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,040 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALLARITY THERAPEUTICS INC finden Sie auf Wallstreet Online.